[A22-77] Pembrolizumab (gastric cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 02.11.2022
Commission awarded on 21.07.2022 by the Federal Joint Committee (G-BA).
Adults with unresectable or metastatic microsatellite instability high or mismatch repair deficient gastric cancer, who have disease progression on or following at least one prior therapy
- Patients who have disease progression on or following at least one prior therapy: hint of non-quantifiable added benefit
- Patients who have disease progression on or following at least 2 prior therapies: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.